INSMED INC Deferred Tax Liabilities, Intangible Assets
INSMED INC (INSM) had Deferred Tax Liabilities, Intangible Assets of $0 as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $0.00.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $5.58M.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $9.14M; Deferred Tax Liabilities, Intangible Assets as first filed $13.01M.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $13.74M.
| Period end | Deferred Tax Liabilities, Intangible Assets | Deferred Tax Liabilities, Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |
| 2024-12-31 | $5.58M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $9.14M 10-K · filed 2025-02-20 | $13.01M 10-K · filed 2024-02-22 |
| 2022-12-31 | $13.74M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $15.21M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $9.16M 10-K · filed 2022-02-17 | |
| 2019-12-31 | $14.32M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $15.42M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $16.36M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |